Sorry, you need to enable JavaScript to visit this website.

A Study Comparing Palbociclib Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Asian Postmenopausal Women with Advanced Breast Cancer

A Multicenter, Randomized, Double-Blind Phase 3 Study of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Previously Untreated Asian Postmenopausal Women with ER (+), HER2 (-) Advanced Breast Cancer

Category & Conditions: Cancer
Medicine: Ibrance (palbociclib) Identifier (NCT): NCT02297438
Protocol ID: A5481027
Open Plain Language Summary Result: Click here